Because low-risk prostate cancer is unlikely to spread or impact survival, experts and guidelines recommend active surveillance, which involves regular monitoring and thus avoid or delay treatment like surgery or radiation therapy and their life-changing complications.
Medacta to Feature GMK SpheriKA and Innovative Personalized Solutions at AAOS 2024 – Biotech Investments
Medacta Group SA / Key word(s): Miscellaneous Medacta to Feature GMK SpheriKA and Innovative Personalized Solutions at AAOS 2024 12.02.2024 / 19:00 CET/CEST MEDIA RELEASE